Company / Return on Equity (ROE)
NextCure, Inc. Return on Equity (ROE) History
FY2020-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-12.5%
FY2021
5-year range
-12.5% / -10.5%
FY2020-FY2021
Trend
-18.8%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
NextCure, Inc. reports negative total equity of -12.5% in FY2021. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-12.5% in FY2021.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2021, return on equity (roe) decreased 18.8% year-over-year.
Company context
Key Data Points
- Altman Z-Score -2.19 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2021 | -12.5% | -18.8% |
| FY2020 | -10.5% | - |
| FY2019 | - | - |
As of FY2021 · SEC 10-K Annual Filings · Updated Jun 28, 2026